Resolution of Allergic Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After an allergen challenge, the allergic inflammatory response disappears spontaneously. The initiation of the resolution of the inflammatory response is now recognized as a dynamic process, involving active biochemical programs that enable inflamed tissues to return to homeostasis. Recent data established key roles of different specific lipid mediators in the endogenous counter-regulation of inflammation and activation of resolution. Only little is known about kinetics of these specialized pro-resolving lipid mediators during acute allergic inflammation. Therefore, the primary propose of our study is to characterize the temporal evolution of cellular inflammation and specific lipid mediators after allergen challenge.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge

NCT01657097

Allergic Rhinitis Asthma

COMPLETED PHASE4

Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber

NCT06104293

Allergic Rhinitis Due to Grass Pollen

COMPLETED NA

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

NCT00812799

Allergic Rhinoconjunctivitis

UNKNOWN PHASE3

Influence of Nutrition on Nasal and Bronchial Affliction in Patients With Allergy on Grass-Pollen

NCT00519740

Bronchial Hyperreactivity Hypersensitivity Allergy +1 more

COMPLETED NA

Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber

NCT03496103

Allergic Rhinitis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Grass Pollen Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

measurement of mediators in biological fluids

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Grass pollen allergen extract

Group Type EXPERIMENTAL

Grass pollen allergen extract

Intervention Type OTHER

Each subject will be challenged with a grass pollen allergen extract and with placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Grass pollen allergen extract

Each subject will be challenged with a grass pollen allergen extract and with placebo.

Intervention Type OTHER

placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Allergic rhinitis during the grass pollen season with or without asthma, with at least one of the following symptoms: nasal congestion, itching, rhinorrhea, sneezing
* Grass pollen sensitization determined by a positive skin prick test and / or presence of specific IgEs to a grass pollen allergen extract

Exclusion Criteria

* Smoker
* Specific immunotherapy with grass allergens or other respiratory allergen for inclusion.
* Current exhibition to another clinically relevant respiratory allergen

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No